Chemotherapy and Targeted Therapy

BioMarin Bolsters Voxzogo Portfolio with Positive Hypochondroplasia Data Amidst Competitive Shift biomarin-bolsters-voxzogo-portfolio-with-positive-hypochondroplasia-data-amidst-competitive-shift

BioMarin Bolsters Voxzogo Portfolio with Positive Hypochondroplasia Data Amidst Competitive Shift

Lina Hope May 21, 2026

In a high-stakes week for BioMarin Pharmaceutical, the company has secured a critical victory that promises to...

Eli Lilly Doubles Down on Genetic Medicine with $202M Acquisition of Engage Biologics eli-lilly-doubles-down-on-genetic-medicine-with-202m-acquisition-of-engage-biologics

Eli Lilly Doubles Down on Genetic Medicine with $202M Acquisition of Engage Biologics

Suro Senen May 21, 2026

By Delilah Alvarado Published May 20, 2026 In a strategic maneuver that underscores the pharmaceutical industry’s pivot...

Canada Breaks the Monopoly: A New Era for Semaglutide Access canada-breaks-the-monopoly-a-new-era-for-semaglutide-access

Canada Breaks the Monopoly: A New Era for Semaglutide Access

Evan Lee Salim May 21, 2026

In a landmark decision that has sent shockwaves through the global pharmaceutical industry, Canada has officially become...

The Silicon Pivot: How Bristol Myers Squibb and Big Pharma Are Betting the Future on Artificial Intelligence the-silicon-pivot-how-bristol-myers-squibb-and-big-pharma-are-betting-the-future-on-artificial-intelligence

The Silicon Pivot: How Bristol Myers Squibb and Big Pharma Are Betting the Future on Artificial Intelligence

Neng Nana May 20, 2026

In a move that signals a seismic shift in the architecture of pharmaceutical research and development, Bristol...

FDA Commissioner Marty Makary Resigns Amidst Administrative Pressure and Policy Turmoil fda-commissioner-marty-makary-resigns-amidst-administrative-pressure-and-policy-turmoil

FDA Commissioner Marty Makary Resigns Amidst Administrative Pressure and Policy Turmoil

Raul Delapena Setiawan May 20, 2026

WASHINGTON, D.C. — In a development that signals a profound shift in the regulatory landscape of the...

The Next Frontier in Migraine Care: Mentari Therapeutics’ Strategic Leap into the Public Markets the-next-frontier-in-migraine-care-mentari-therapeutics-strategic-leap-into-the-public-markets

The Next Frontier in Migraine Care: Mentari Therapeutics’ Strategic Leap into the Public Markets

Raul Delapena Setiawan May 19, 2026

In a transformative move for the neurology sector, privately held biotech firm Mentari Therapeutics has announced a...

Regeneron’s Pipeline Under Scrutiny: Fianlimab Setback Sparks Strategic Questions for Biotech Giant regenerons-pipeline-under-scrutiny-fianlimab-setback-sparks-strategic-questions-for-biotech-giant

Regeneron’s Pipeline Under Scrutiny: Fianlimab Setback Sparks Strategic Questions for Biotech Giant

Nana Wu May 19, 2026

By Ben Fidler | Published May 18, 2026 Regeneron Pharmaceuticals, long considered a gold standard in the...

Engineering Biology: Cellular Intelligence Acquires Novo Nordisk’s Landmark Parkinson’s Therapy engineering-biology-cellular-intelligence-acquires-novo-nordisks-landmark-parkinsons-therapy

Engineering Biology: Cellular Intelligence Acquires Novo Nordisk’s Landmark Parkinson’s Therapy

Basiran May 19, 2026

In a high-stakes pivot that signals the maturation of AI-driven biotechnology, the startup Cellular Intelligence (formerly known...

Merck’s Oncology Pivot: Sac-TMT Success Marks Critical Milestone in Post-Keytruda Era mercks-oncology-pivot-sac-tmt-success-marks-critical-milestone-in-post-keytruda-era

Merck’s Oncology Pivot: Sac-TMT Success Marks Critical Milestone in Post-Keytruda Era

Nana Wu May 18, 2026

By Jonathan Gardner Published May 18, 2026 In a high-stakes move to secure its long-term market dominance,...

The “Vibe-Coded” Unicorn Under Fire: Medvi’s Risky Gamble with Unapproved Drug Cocktails the-vibe-coded-unicorn-under-fire-medvis-risky-gamble-with-unapproved-drug-cocktails

The “Vibe-Coded” Unicorn Under Fire: Medvi’s Risky Gamble with Unapproved Drug Cocktails

Nana May 18, 2026

In the fast-moving world of telehealth, few companies have captured the public imagination—or the ire of regulators—quite...

Chemotherapy and Targeted Therapy

BioMarin Bolsters Voxzogo Portfolio with Positive Hypochondroplasia Data Amidst Competitive Shift

Eli Lilly Doubles Down on Genetic Medicine with $202M Acquisition of Engage Biologics

Canada Breaks the Monopoly: A New Era for Semaglutide Access

The Silicon Pivot: How Bristol Myers Squibb and Big Pharma Are Betting the Future on Artificial Intelligence

FDA Commissioner Marty Makary Resigns Amidst Administrative Pressure and Policy Turmoil

The Next Frontier in Migraine Care: Mentari Therapeutics’ Strategic Leap into the Public Markets

Regeneron’s Pipeline Under Scrutiny: Fianlimab Setback Sparks Strategic Questions for Biotech Giant

Engineering Biology: Cellular Intelligence Acquires Novo Nordisk’s Landmark Parkinson’s Therapy

Merck’s Oncology Pivot: Sac-TMT Success Marks Critical Milestone in Post-Keytruda Era

The “Vibe-Coded” Unicorn Under Fire: Medvi’s Risky Gamble with Unapproved Drug Cocktails

You may have missed

Ibuprofen: Beyond Pain Relief – Unveiling its Unexpected Anti-Cancer Potential

A Paradigm Shift in HIV Care: Gilead and Merck’s Once-Weekly Regimen Passes Phase 3 Milestone

Beyond Wrinkles: The Emerging Role of Botox in Revolutionizing Scar Management

The Radiology Crisis: Escalating Costs and Workforce Shortages Threaten Patient Care